Keyphrases
Ado-trastuzumab
50%
Adverse Events
20%
American Academy of Dermatology
11%
Arrhythmias Cardiac
50%
Clinical Outcomes
10%
Clinical Practice Guidelines
55%
Clinical Testing
10%
Clinical Trials
50%
Cochrane Systematic Review
21%
Consolidated Standards of Reporting Trials (CONSORT)
70%
Cystic Fibrosis
50%
Dermatology Journals
50%
Drug Development
50%
Drug Efficacy
10%
European Society of Cardiology
50%
FDA-approved Drugs
20%
Inclusion Criteria
14%
Journal Publishing
50%
Measuring Instrument
35%
Median Progression-free Survival
10%
Meta-analysis
48%
Methodological Quality
21%
Objective Response Rate
20%
Outcome Reporting
19%
Patient Benefit
50%
Patient Care
12%
Patient Outcomes
50%
Patient Risk
50%
Patient-reported Outcomes
83%
Patient-Reported Outcomes Measurement Information System (PROMIS)
50%
Predatory Journals
50%
Predatory Publications
22%
Quality of Life
13%
Randomized Controlled Trial
100%
Reporting Item
42%
Reporting Quality
80%
Risk of Bias
54%
Risk Outcomes
50%
Risk-benefit
50%
Rotator Cuff Tear
50%
Sectional Analysis
57%
Shoulder Rotator Cuff
50%
Sudden Cardiac Death
50%
Survival Response
10%
Systematic Meta-analysis
48%
T-DM1
50%
Trastuzumab Emtansine
10%
Treatment Burden
10%
Trial Characteristics
25%
Ventricular Arrhythmia
50%
Medicine and Dentistry
Cardiology
50%
Cross Sectional Study
52%
Cystic Fibrosis
50%
Dermatology
50%
Heart Ventricle Arrhythmia
50%
Medical Decision Making
5%
Meta-Analysis
18%
Patient Care
16%
Patient-Reported Outcome
100%
Randomized Controlled Trial
100%
Rotator Cuff Injury
50%
Sudden Cardiac Death
50%
Systematic Review
100%
Nursing and Health Professions
Cochrane Library
6%
Cystic Fibrosis
50%
Embase
6%
Heart Ventricle Arrhythmia
50%
Meta Analysis
13%
Patient Care
5%
Patient-Reported Outcome
100%
Practice Guideline
53%
Rotator Cuff Injury
50%
Sudden Cardiac Death
50%
Systematic Review
50%
